We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 13 juni 2018

The Lancet: [Department of Error] Department of Error

[Department of Error] Department of Error
Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 2018; 391: 1683–92—In this Article, the adjusted difference between the HRSD-17 scores listed in the abstract should have been 0·103 points. This correction has been made to the online version as of June 11, 2018.
Read more

[Department of Error] Department of Error
Psoriatic arthritis: classification and holistic management. Lancet 2018; 391: 2185—In this Editorial, the abbreviation for the Classification of Psoriasis Arthritis criteria should have been "CASPAR". This correction has been made to the online version as of June 11, 2018.
Read more

[Editorial] France may be back, but the old ways persist for INSERM
On June 12, the term of the Chief Executive Officer (CEO) of the French National Institute of Health and Medical Research (INSERM) ends. The office of the current CEO, Yves Lévy, came under heavy criticism after the appointment of the minister of health, Agnès Buzyn, in May, 2017. Lévy is Buzyn's husband, an obvious potential conflict of interest for the head of an institute that is run under the dual auspices of the Ministries of Health and Research. This discrepancy was seemingly rectified, on May 29, 2017, by a decree stating that acts relating to INSERM would be carried out by the French prime minister, not Buzyn.
Read more

[Articles] Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Patients with moderately to severely active rheumatoid arthritis who received upadacitinib (15 mg or 30 mg) in combination with csDMARDs showed significant improvements in clinical signs and symptoms.
Read more

[Articles] Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Both doses of upadacitinib led to rapid and significant improvements compared with placebo over 12 weeks in patients with refractory rheumatoid arthritis.
Read more